ACBD3

Across TCGA pan-cancer cohorts, ACBD3 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ACBD3 data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ACBD3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ACBD3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and COAD show a favorable association.

PDAC, LSCC, and CCRCC are the cancer types where ACBD3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	II,III,IV	0.866	0.670	<.001	76	view →
LSCC	DFS	Quartile	II,III,IV	0.377	0.860	<.001	31	view →
CCRCC	OS	Median	All	0.618	1.000	.001	20	view →
COAD	DFS	Median	III,IV	1.000	0.835	.032	18	view →
LUAD	OS	Median	III,IV	0.738	0.269	.008	16	view →
UCEC	DFS	Tertile	All	0.973	0.875	.032	4	view →
HNSC	DFS	Tertile	III,IV	0.900	0.695	.026	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ACBD3–PDAC (DFS)

Open the PDAC breakdown →